These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18194306)

  • 1. A haemophilia B patient with severe burn injury: increased requirement for factor IX replacement therapy associated with venous thromboembolism.
    Yaish H; Rodgers GM
    Haemophilia; 2008 May; 14(3):607-9. PubMed ID: 18194306
    [No Abstract]   [Full Text] [Related]  

  • 2. Spinal epidural haematoma in a patient with haemophilia B.
    Balkan C; Kavakli K; Karapinar D
    Haemophilia; 2006 Jul; 12(4):437-40. PubMed ID: 16834748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañes M; Paez A
    Haemophilia; 2010 Mar; 16(2):240-6. PubMed ID: 20015218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of third molar removal with a single dose of recombinant Factor IX (BeneFIX) and local measures in severe haemophilia B.
    Hewson ID; Makhmaloaf P
    Aust Dent J; 2010 Sep; 55(3):322-4. PubMed ID: 20887522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The international factor IX treatment network survey.
    Berntorp E; Shapiro AD; Waters J; Astermark J;
    Haemophilia; 2012 May; 18(3):e60-2. PubMed ID: 22404549
    [No Abstract]   [Full Text] [Related]  

  • 6. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.
    Thorland EC; Drost JB; Lusher JM; Warrier I; Shapiro A; Koerper MA; Dimichele D; Westman J; Key NS; Sommer SS
    Haemophilia; 1999 Mar; 5(2):101-5. PubMed ID: 10215957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of OCTANINE F in children with haemophilia B.
    Klukowska A; Laguna P; Svirin P; Shiller E; Vdovin V
    Haemophilia; 2008 May; 14(3):531-8. PubMed ID: 18355266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
    Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
    Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune tolerance: critical issues of factor dose, purity and treatment complications.
    DiMichele DM
    Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative factor IX replacement for surgical resection of a suprasellar astrocytoma in a child with severe haemophilia B.
    Walker JA; Dixon N; Gururangan S; Thornburg C
    Haemophilia; 2008 Mar; 14(2):387-9. PubMed ID: 18194312
    [No Abstract]   [Full Text] [Related]  

  • 11. Identical but different: haemophilia B in monozygotic twins with inhibitor in one brother and subsequent successful immune tolerance induction.
    Ranta S; Verbruggen B; Wikström A; Mäkipernaa A
    Haemophilia; 2012 Jul; 18(4):e349-51. PubMed ID: 22631443
    [No Abstract]   [Full Text] [Related]  

  • 12. [A controlled study of long-term treatment of haemophilia B on an out-patient basis (author's transl)].
    Schimpf K; Baumann P
    Dtsch Med Wochenschr; 1976 Feb; 101(7):233-8. PubMed ID: 1248406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the treatment of haemophilia B: laboratory and clinical perspectives.
    Aledort LM
    Haemophilia; 2010 Jul; 16 Suppl 6():1-2. PubMed ID: 20561350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
    Berntorp E; Keeling D; Makris M; Tagliaferri A; Male C; Mauser-Bunschoten EP; Musso R; Roca CA; Hassoun A; Kollmer C; Charnigo R; Baumann J; Rendo P
    Haemophilia; 2012 Jul; 18(4):503-9. PubMed ID: 22044794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M; Shirahata A
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery.
    Schulman S; Wallensten R; White B; Smith OP
    Haemophilia; 1999 Mar; 5(2):96-100. PubMed ID: 10215956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current management of hemophilia B.
    Roberts HR; Eberst ME
    Hematol Oncol Clin North Am; 1993 Dec; 7(6):1269-80. PubMed ID: 8294316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium content in products used to treat haemophilia.
    Altisent C; Martorell M; de la Sierra A
    Haemophilia; 2016 Jul; 22(4):e324-7. PubMed ID: 27228069
    [No Abstract]   [Full Text] [Related]  

  • 19. Cataract surgery in haemophilia.
    Mauser-Bunschoten EP; Bijlsma W; Roosendaal G; Schutgens RE
    Haemophilia; 2013 Nov; 19(6):e371-2. PubMed ID: 23773276
    [No Abstract]   [Full Text] [Related]  

  • 20. Progressive improvement in wound healing with increased therapy in haemophilia B mice.
    Monroe DM; Hoffman M; Roberts HR; Hedner U
    Haemophilia; 2013 Nov; 19(6):926-32. PubMed ID: 23879625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.